Thelansis

Autosomal Recessive Congenital Ichthyosis (ARCI) Market Outlook Thelansis’s “Autosomal Recessive Congenital Ichthyosis (ARCI) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Autosomal Recessive Congenital Ichthyosis (ARCI) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Key business questions answered: How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)? How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments? What is the 10-year market outlook for sales and patient shar...

Autosomal Recessive Congenital Ichthyosis (ARCI) Market Outlook Thelansis’s “Autosomal Recessive Congenital Ichthyosis (ARCI) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Autosomal Recessive Congenital Ichthyosis (ARCI) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Autosomal Recessive Congenital Ichthyosis (ARCI) Overview Autosomal recessive congenital ichthyosis (ARCI) is a heterogeneous group of keratinization disorders recognized by abnormal skin scaling over the entire body and classified as non-syndromic and syndromic forms of ichthyosis. ABCA12, ALOX12B, ALOXE3, CASP14, CERS3, CYP4F22, LIPN, NIPAL4, PNPLA1, SDR9C7, ...

  Autosomal recessive congenital ichthyosis (ARCI) is a heterogeneous group of keratinization disorders recognized by abnormal skin scaling over the entire body and classified as non-syndromic and syndromic forms of ichthyosis. ABCA12, ALOX12B, ALOXE3, CASP14, CERS3, CYP4F22, LIPN, NIPAL4, PNPLA1, SDR9C7, SLC27A4, and TGM1 are the twelve genes known to be involved with ARCI; at least 15% of affected families do not have pathogenic variants in any of the known genes. 60% to 70% of the patients have severe symptoms such as collodion membrane at birth. The two main phenotypes are lamellar ichthyosis and congenital ichthyosiform erythroderma; however, phenotypic overlap can occur in the same patient or patients from the same family. Some patient exhibits nonlamellar, non-erythrodermic ichthyosis. It also includes harlequin ichthyosis, acral self-healing collodion baby, self-healing collodion baby, and bathing suit ichthyosis. The estimated prevalence at birth of 1 per 100 000 popul...